Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme

REFERENCES

1. 1.↵
   1. Stupp R,
   2. Hegi ME,
   3. Mason WP,
   4. et al

   . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Reardon DA,
   2. Galanis E,
   3. DeGroot JF,
   4. et al

   . Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011;13:353–61

   Abstract/FREE Full Text
3. 3.↵
   1. van den Bent MJ,
   2. Vogelbaum MA,
   3. Wen PY,
   4. et al

   . End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009;27:2905–08

   FREE Full Text
4. 4.↵
   1. Iliadis G,
   2. Kotoula V,
   3. Chatzisotiriou A,
   4. et al

   . Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer 2012;12:3

   CrossRefPubMed
5. 5.↵
   1. Dempsey MF,
   2. Condon BR,
   3. Hadley DM

   . Measurement of tumor “size” in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol 2005;26:770–76

   Abstract/FREE Full Text
6. 6.↵
   1. Schwartz LH,
   2. Ginsberg MS,
   3. DeCorato D,
   4. et al

   . Evaluation of tumor measurements in oncology: use of film-based and electronic techniques. J Clin Oncol 2000;18:2179–84

   Abstract/FREE Full Text
7. 7.↵
   1. Therasse P,
   2. Arbuck SG,
   3. Eisenhauer EA,
   4. et al

   . New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16

   Abstract/FREE Full Text
8. 8.↵
   1. Macdonald DR,
   2. Cascino TL,
   3. Schold SC Jr.,
   4. et al

   . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80

   Abstract
9. 9.↵
   1. Eisenhauer EA,
   2. Therasse P,
   3. Bogaerts J,
   4. et al

   . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Henson JW,
    2. Ulmer S,
    3. Harris GJ

    . Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29:419–24

    Abstract/FREE Full Text
11. 11.↵
    1. Wen PY,
    2. Macdonald DR,
    3. Reardon DA,
    4. et al

    . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72

    Abstract/FREE Full Text
12. 12.↵
    1. Welsh JL,
    2. Bodeker K,
    3. Fallon E,
    4. et al

    . Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. Am J Surg 2012;204:580–85

    CrossRefPubMed
13. 13.↵
    1. Zhao B,
    2. Oxnard GR,
    3. Moskowitz CS,
    4. et al

    . A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16:4647–53

    Abstract/FREE Full Text
14. 14.↵
    1. Mozley PD,
    2. Bendtsen C,
    3. Zhao B,
    4. et al

    . Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol 2012;5:19–25

    PubMed
15. 15.↵
    1. Kanaly CW,
    2. Ding D,
    3. Mehta AI,
    4. et al

    . A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 2011;6:e16031

    CrossRefPubMed
16. 16.↵
    1. Egger J,
    2. Kapur T,
    3. Fedorov A,
    4. et al

    . GBM volumetry using the 3D Slicer medical image computing platform. Sci Rep 2013;3:1364

    PubMed
17. 17.↵
    1. Zhu Y,
    2. Young GS,
    3. Xue Z,
    4. et al

    . Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation. Acad Radiol 2012;19:977–85

    CrossRefPubMed
18. 18.↵
    Computer-aided tumor segmentation using local region-based active contours. Columbia University Invention Report IR #2906
19. 19.↵
    Methods and Systems for Segmentation of Organs and Tumors and Objects. Patent (pending) PCT/US13/36166. April, 2013
20. 20.↵
    1. Zaretsky J,
    2. Guo X,
    3. Fu J,
    4. et al

    . Novel radiologic features to predict hepatocellular carcinoma recurrence after liver transplantation: a pilot study. In: 62nd Annual Meeting of the American Association for the Study of Liver diseases (AASLD), San Francisco, California. Nov 3–8, 2011
21. 21.↵
    1. Abou-Alfa GK,
    2. Zhao B,
    3. Capanu M,
    4. et al

    . Effects of Radiologic Tumor Response of Anti-Glypican 3 GC33 and Multi Tyrosine Kinases Inhibitor Sorafenib in Hepatocellular Carcinoma. In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Dublin, Ireland. November 6–9, 2012
22. 22.↵
    1. Leinwand J,
    2. Zhao B,
    3. Guo X,
    4. et al

    . Quantitative CT peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol 2013 May 24. [Epub ahead of print]
23. 23.↵
    1. Sorensen AG,
    2. Patel S,
    3. Harmath C,
    4. et al

    . Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19:551–57

    Abstract/FREE Full Text
24. 24.↵
    1. Provenzale JM,
    2. Mancini MC

    . Assessment of intra-observer variability in measurement of high-grade brain tumors. J Neurooncol 2012;108:477–83

    CrossRefPubMed
25. 25.↵
    1. Provenzale JM,
    2. Ison C,
    3. Delong D

    . Bidimensional measurements in brain tumors: assessment of interobserver variability. AJR Am J Roentgenol 2009;193:W515–22

    CrossRefPubMed
26. 26.↵
    1. Sorensen AG,
    2. Batchelor TT,
    3. Wen PY,
    4. et al

    . Response criteria for glioma. Nat Clin Pract Oncol 2008;5:634–44

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Keles GE,
    2. Lamborn KR,
    3. Chang SM,
    4. et al

    . Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004;100:41–46

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Lacroix M,
    2. Abi-Said D,
    3. Fourney DR,
    4. et al

    . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–98

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Warren KE,
    2. Patronas N,
    3. Aikin AA,
    4. et al

    . Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001;93:1401–05

    Abstract/FREE Full Text
30. 30.↵
    1. Gladwish A,
    2. Koh ES,
    3. Hoisak J,
    4. et al

    . Evaluation of early imaging response criteria in glioblastoma multiforme. Radiat Oncol 2011;6:121

    CrossRefPubMed